The aim of the present study is to investigate the potency of the novel p53 stabilizing peptide VIP116 and 177Lu-DOTATATE, both as monotherapies and in combination, in multicellular neuroblastoma tumor spheroids. The gene discussed is TP53; the disease is neoplasm.